Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Frequently asked questions
What sector does Adverum Biotechnologies, Inc (ADVM) operate in?
Adverum Biotechnologies, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Adverum Biotechnologies, Inc (ADVM) current stock price?
As of the latest data, Adverum Biotechnologies, Inc stock price is $4.36, with a previous close of $4.36.
What is Adverum Biotechnologies, Inc (ADVM) current market capitalization?
Adverum Biotechnologies, Inc market cap is approximately 96.26 million.
What is Adverum Biotechnologies, Inc (ADVM) Earnings Per Share (EPS)?
The trailing EPS is -$8.57, and the forward EPS is -$4.16.
Does Adverum Biotechnologies, Inc (ADVM) pay dividends?
No. Adverum Biotechnologies, Inc does not pay a dividend.
What is Adverum Biotechnologies, Inc (ADVM) beta (volatility) score?
Adverum Biotechnologies, Inc has a beta of 0.868, meaning its volatility is roughly in line with the market.
